In summary, we view the new sales orders as a positive step forward. With the planned divestment of berry extract manufacturing assets, these orders further validate the strong demand for Eevia’s high-quality plant extracts, highlighting the potential to unlock significant underlying value upon successful completion of the divestment.

Read Analyst Group’s comment on the news
Read Analyst Group’s comment on Eevia Health and the rights issue here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Eevia Health. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.